XOMA Corporation (XOMA) : 1 brokerage houses believe that XOMA Corporation (XOMA) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on XOMA Corporation (XOMA). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Hold with a rating of 2.6.
XOMA Corporation (XOMA) : The highest level XOMA Corporation (XOMA) is projected to reach is $3 for the short term and the lowest estimate is at $1. The consolidated price target from 3 rating analysts who initiate coverage on the stock is $1.62 and the possibility the share price can swing is $1.2.
Company shares have received an average consensus rating of Hold for the current week XOMA Corporation (NASDAQ:XOMA): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.61 and $0.60 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.61, notching a gain of 1.12% for the day. The total traded volume was 284,200 . The stock had closed at $0.60 on the previous day.
In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (VP, Finance & Chief Financial) of Xoma Corp, Burns Thomas M. had sold 19,249 shares worth of $15,207 in a transaction dated March 22, 2016. In this transaction, 19,249 shares were sold at $0.79 per share.
XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).